News

Abzena plc has entered into a master service agreement with one of America’s leading academic medical centres, NYU Langone Health (New York, US). The agreement, for protein engineering…
Read More...

AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) announced that the European Medicines Agency (EMA) has granted orphan designation to…
Read More...

Amgen announced the groundbreaking of its new next-generation biomanufacturing plant that will be constructed at its West Greenwich, R.I. campus. The new plant is the first-of-its-kind…
Read More...

PTC Therapeutics and Akcea Therapeutic an affiliate of Ionis Pharmaceuticals announced a collaboration under which PTC will commercialize two of Akcea's rare disease drugs in Latin…
Read More...

Roche announced that the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) designation for the company’s investigational medicine RG6042 (formerly known as…
Read More...

Novartis announced that the European Commission (EC) approved Aimovig (erenumab) for the prevention of migraine in adults experiencing four or more migraine days per month. Aimovig is…
Read More...

AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) announced that the European Medicines Agency (EMA) has granted orphan designation to…
Read More...

Takeda Pharmaceutical Company Limited announced the opening of a production site for NINLARO (ixazomib), an innovative drug for patients with multiple myeloma, at its Yaroslavl plant.…
Read More...

Pfizer Inc. announced the European Commission (EC) has approved TRAZIMERA, a biosimilar to Herceptin (trastuzumab), for the treatment of human epidermal growth factor (HER2)…
Read More...

Shionogi & Co., Ltd. announced that, after completing a Priority Review, the U.S. Food and Drug Administration (FDA) has approved Mulpleta (lusutrombopag), a once-daily, orally…
Read More...

Abdi Ibrahim has carefully selected rfxcel to implement and support new compliance management and serialisation processing software to ensure full compliance with current and future…
Read More...

Torque, an immuno-oncology company developing first-in-class Deep Primed T Cell Therapeutics to direct immune power deep within the tumor microenvironment, announced today a…
Read More...

Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, announced that, based on achievement of technical milestones, it has…
Read More...

Nutriband Inc announced the formal completion of the acquisition of Atlanta-based 4P Therapeutics Inc. Pursuant to the previously announced acquisition agreement, on Aug 1, 2018,…
Read More...

Puma Biotechnology announced that Health Canada has accepted for review the Company’s New Drug Submission (NDS) for the medicinal product NERLYNX (neratinib) for the extended adjuvant…
Read More...

LEO Pharma and Bayer announced that LEO Pharma has entered into a definitive agreement to buy Bayer’s global prescription dermatology unit. The portfolio to be acquired includes branded…
Read More...

Takeda Pharmaceutical Company Limited and TiGenix NV announced that Takeda has acquired all outstanding ordinary shares (including Ordinary Shares represented by American Depositary…
Read More...

IBSA Group, the largest privately owned pharmaceutical company in Switzerland, has established a commercial presence in the United States as IBSA Pharma Inc. and is planning to directly…
Read More...

HiFiBiO Therapeutics announced a multi-target agreement with Takeda Pharmaceutical Company Limited (Takeda) to enable the discovery of breakthrough antibody therapies to potentially…
Read More...

Nektar Therapeutics announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for review the company's New Drug Application (NDA) for NKTR-181 for the treatment…
Read More...